Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
This session will cover:
The basics of TK2d, including its genetic cause, symptoms, and how it is diagnosed
The impact of TK2d on patients and families
An overview of KYGEVVI, including how it works and who may be eligible for treatment
Important safety information and what to expect with therapy
For full prescribing information and important safety details, please visit https://www.kygevvi.com/.
Dr. Amy Goldstein will join MitoAction to review the neurological system and the differences between types of neuropathies. She will explore what conditions neuropathy...
Frustrated with the run-around from health insurance companies? Join us this month as we discuss strategies for advocating for the diagnosis, management, and treatment...
Join licensed school psychologist, Gena Padgett and high school history teacher / FAOD mom, Beth Folcher to prepare yourself for sending your child(ren) back...
